News & Updates
Filter by Specialty:
Superior IBD control achieved with biomarker-guided therapy standard care
Biomarker-informed molecular guidance improves anti-TNF therapy outcomes in patients with inflammatory bowel disease (IBD), increasing the likelihood of achieving disease control when compared with standard “best care,” as shown in the GUIDE-IBD trial.
Superior IBD control achieved with biomarker-guided therapy standard care
26 May 2025
No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer
Statin use was not associated with improved survival outcomes in the phase III APHINITY trial investigating the addition of pertuzumab to trastuzumab and chemotherapy as adjuvant treatment for patients with early HER2-positive breast cancer (BC).
No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer
26 May 2025
Full-spectrum microbiome drug for IBS with constipation clears phase II trial
The next-generation oral full-spectrum microbiome drug EBX-102-02 appears to have an acceptable safety profile in patients with irritable bowel syndrome with constipation (IBS-C) while yielding improvements in symptom severity, abdominal pain, and stool consistency, according to the results of the phase IIa TrIuMPH* study.